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Abstract
Importance—Although early mortality in severe psychiatric illness is linked to smoking and
alcohol, no studies have comprehensively characterized substance use behavior in severe
psychotic illness. In particular, recent assessments of substance use in individuals with mental
illness are based on population surveys that do not include individuals with severe psychotic
illness.
Objective—To compare substance use in individuals with severe psychotic illness to substance
use in the general population.
Design—We assessed comorbidity between substance use and severe psychotic disorders in the
Genomic Psychiatry Cohort (GPC). The GPC is a clinically assessed, multi-ethnic sample
consisting of 9,142 individuals with the diagnosis of schizophrenia, bipolar disorder with
psychotic features, or schizoaffective disorder, and 10,195 population controls.
Primary Outcome Measures—Smoking (smoked > 100 cigarettes lifetime), heavy alcohol use
(> 4 drinks/day), heavy marijuana use (>21 times of marijuana use in a single year), and
recreational drug use.
Results—Relative to the general population, individuals with severe psychotic disorders have
increased risk of smoking (OR 4.6, 95% CI 4.3-4.9), heavy alcohol use (OR 4.0, 95% CI 3.6-4.4),
heavy marijuana use (OR 3.5, 95% CI 3.2-3.7), and recreational drug use (OR 4.6, 95% CI
4.3-5.0). All ethnicities (African American, Asian, European American, and Hispanics) and both
sexes have greatly elevated risks of smoking, alcohol, marijuana, and drug use. Of specific
concern, recent public health efforts that have successfully decreased smoking among individuals
under age 30 appear to have been ineffective among individuals with severe psychotic illness (p-
value for interaction effect between age and severe mental illness on smoking initiation P=4.5 ×
10−5).
Conclusions and Relevance—In the largest assessment of substance use among individuals
with severe psychotic illness to date, we found odds of smoking, alcohol, and other substance use
to be dramatically higher than recent estimates of substance use in mild mental illness.
Individuals with severe mental illness die approximately 25 years earlier than the general
population and the cause of this early death is largely due to medical illness that can be
attributed to substance use disorders 1-3. For example, although suicide and injury are more
common among individuals with chronic mental illness, 60% of premature deaths in persons
with schizophrenia are due to medical conditions including heart and lung disease and
infectious illness caused by modifiable risk factors such as smoking, alcohol consumption,
and IV drug use1. In addition to early mortality, the severity and prognosis of the primary
mental illness is worsened in the context of substance dependence 4,5.
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The 2009-2011 National Survey on Drug Use and Health (NSDUH) identified adults with
mental illness (based on 14-items related to psychological distress and disability) and found
that 36% of adults with mental illness are current smokers, relative to 21% of adults without
mental illness 6. In addition, they found that adult smokers with mental illness are less likely
to quit than adult smokers without mental illness. This discrepancy highlights the public
health disparity in the mentally ill, a uniquely vulnerable population.
In addition to increased smoking among individuals with mental illness, alcohol and other
substance use disorders have increased prevalence in individuals with mental illness 7-17.
Several large epidemiological surveys have assessed comorbidity of affective and psychotic
illness with tobacco, alcohol and drug use disorders in the general population 8,9,12,16,18-20.
In these studies, alcohol and drug dependence were found to be more than twice as common
among individuals with anxiety disorders, affective disorders, and psychotic
disorders9,10,13,16,21. There is also evidence that associations between substance use/
dependence and other psychiatric illness are true for both men and women 18, and extend to
African Americans 22 and Hispanics 7.
Despite strong epidemiological studies of the general population showing increased
comorbidity of smoking, alcohol, and drug use in mental illness, these studies do not address
comorbidity of smoking, alcohol and drug use in severe psychotic illness. Not only is severe
psychotic illness rare in the general population, but individuals with severe psychotic illness
are difficult to contact in general population surveys, and so there is no large-scale survey of
substance use among clinically ascertained individuals with severe psychotic illness.
Specifically, it is unknown whether the rates of substance use among individuals with mild
mental illness, as ascertained in population surveys, apply to individuals with severe
psychosis. To address this issue, we assessed substance use in a large, multi-ethnic sample
of individuals with schizophrenia, schizoaffective disorder, or bipolar disorder with
psychotic features, and corresponding population controls. Using this powerful sample, we
are able to not only gain insight into substance use among individuals with severe psychosis,
but also determine the differences in substance use between genders, and racial/ethnic
subgroups.
Methods
The Genomic Psychiatry Cohort (GPC) program is a multi-institutional collaboration 23.
This resource includes a NIMH managed repository of genomic samples and detailed
clinical and demographic data for investigations of schizophrenia and bipolar disorder. The
current sample consists of 9,142 individuals with either the diagnosis of schizophrenia,
schizoaffective disorder, or bipolar disorder with psychotic features, and 10,195 population
controls. Individuals with bipolar disorder without psychotic features represented a
relatively small subgroup (n=621) and are therefore not included in these analyses.
Psychiatric diagnoses
Individuals were collected through 12 clinical collaborating sites across the United States.
All individuals ascertained to the GPC completed a screening questionnaire eliciting
demographic (e.g., race, ethnicity, gender) data as well as a brief personal and family
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psychiatric and medical history. Individuals with psychotic illness were ascertained as in-
patients in acute care or chronic care facilities, and out-patient settings. Control subjects
were drawn from the same geographic area as cases, either within health care facilities or as
community volunteers recruited from internet advertising or community groups (e.g. church
congregations, health fair attendees) and screened to ensure absence of schizophrenia or
bipolar disorder within themselves and their first degree relatives.
To confirm the psychiatric diagnoses, case subjects were interviewed by trained clinicians
using a structured psychiatric interview instrument, the Diagnostic Interview for Psychosis
and Affective Disorder (DI-PAD). The DI-PAD is based on the Diagnostic Interview for
Genetic Studies (DIGS24) and includes 90 phenomenological symptom items that are used
with the Operational Criteria Checklist (OPCRIT) computer algorithm 25 to arrive at
diagnoses using Diagnostic and Statistical Manual of Mental Disorders (DSM)26).
Clinicians confirmed diagnoses for schizophrenia, schizoaffective disorder, or bipolar
disorder with psychosis based on DSM-IV criteria.
Substance use measurements
As part of the screening questionnaire, a set of questions were asked of all participants
regarding the individual's substance use. The questions were adapted from the DIGS 24, and
other validated instruments 27,28.
1. Do you often have more than 4 drinks in one day?
2. Over your lifetime, have you smoked more than 100 cigarettes?
3. Have you ever had a period of one month or more when you smoked cigarettes
every day?
4. Have you ever smoked marijuana more than 21 times in a single year?
5. Have you ever used recreational (street) drugs [other than marijuana] or
prescription drugs more than 10 times to feel good or get high?
Epidemiological Sample
To benchmark our sample with epidemiological studies, we looked at items in the National
Survey on Drug Use and Health (NSDUH), a population-based epidemiological survey on
substance use 29. Because the controls used for this dataset were drawn almost exclusively
from the Los Angeles area, we restricted the surveyed data to subjects age 20-55 from
California. We used the following items, directly corresponding to the substance use
measurements in the GPC:
1. During the past 30 days ... on how many days did you have 5 or more drinks on the
same occasion (DR5DAY)? [an answer of > 3 (weekly or more) was used to
correspond to GPC item 1]
2. Have you smoked 100 cigarettes in your entire life (CIG100LF)?
3. Has there ever been a period in your life when you smoked cigarettes every day for
at least 30 days (CIGDLYMO)?
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4. Total # of days used marijuana in the past 12 months (MJYRTOT). [an answer of >
0 was used to correspond to GPC item 4]
5. Illicit drug use (except marijuana), past year (IEMYR).
Statistical analysis
The goal of this study is to evaluate substance use in individuals with chronic psychotic
disorders (cases) as compared to population controls. With the 5 measures listed above as
independent variables, we used logistic regression to model the probability of substance use
based on case/control status, adjusted for race & ethnicity, gender, age (< age 30, age 30-49,
or ≥ age 50), and recruitment site. We also evaluated whether there are significant
interactions on substance use between case control status and race & ethnicity, gender, or
age. All analyses were performed using SAS 9.2 for Windows30.
Results
Table 1 compares the demographics of the sample across controls and the four psychiatric
diagnoses that constitute our sample of individuals with chronic psychotic disorder:
schizophrenia, schizoaffective disorder depressed subtype, schizoaffective disorder bipolar
subtype, and bipolar disorder with psychotic features. The sample used for this study is a
multi-ethnic sample, including African Americans, Asians, European Americans and
Hispanics. There are more female subjects with bipolar disorder than with schizophrenia
(p<0.001). There is a wide age range among all individuals, although cases are older than
the controls in this sample (p<0.001). Therefore, further analyses evaluate associations
between the severe psychotic disorders and substance use only after adjusting for race/
ethnicity, age, and gender.
The prevalence of various measures of substance use are much higher among individuals
with schizophrenia, schizoaffective disorder (both depressed and bipolar subtype), and
bipolar disorder with psychotic features (Table 2). For ease of interpretation, we classified
individuals with schizophrenia, schizoaffective disorders, and bipolar disorder with
psychotic features as “cases with severe psychotic disorder,” and analyzed substance use
with respect to case/control status. The prevalence of these measures is uniformly high in
individuals with severe psychotic illness relative to the control populations. The odds ratio
of cases versus controls for each measure of substance use is given in Table 3. Overall, the
smoking measures were more strongly associated with case/control status than alcohol or
other drugs, with estimated odds ratios of 4.61 for smoking >100 cigarettes (p < 1.0 E-325),
and 5.11 for daily smoking >1 month (p<1.0 E-325). The estimated odds ratios for alcohol
use (OR 3.96, p=1.2 E-188), marijuana use (OR 3.47, p=2.6 E-254), and recreational drug
use (OR 4.62, p<1.0 E-325) were also highly clinically and statistically significant.
Although the prevalence of measures of substance use across gender, race/ethnic group, and
age group varies, it is markedly higher among individuals with psychotic illness within each
group. We tested whether the association between substance measures and case/control
status is stronger within each group (i.e. whether there is a statistical interaction between
case/control status and group). All the items measured showed similar patterns of
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association. For illustrative purposes, Figure 1 illustrates select associations between
substance use and severe psychosis. In groups where the controls had lower rates of
substance use (Asians and Hispanics relative to European Americans, females relative to
males, and individuals under age 30 relative to 30-50 year olds), the odds ratios were
significantly higher than the reference odds ratios, leading to statistically significant
interaction effects. This suggests that although belonging to certain groups may be
protective for substance use in the control population, this protective effect is lost with the
development of a severe mental illness. For example women are at lower risk for using
recreational drugs in the general population (7% of women versus 18% of men in the
general population have used recreational drugs at least 10 times), but the rates of
recreational drug use are much more comparable between men and women among
individuals with severe psychosis (37% of women versus 45% of men with severe psychosis
have used recreational drugs at least 10 times).
Discussion
Individuals with severe mental illness bear an enormous burden due to smoking, alcohol and
drug use. In a large, multi-ethnic sample we found substance use among individuals with
severe psychotic disorder to be markedly higher than in population controls at a rate that far
exceeds previous estimates based on assessments in individuals with mild mental illness 6.
This association extends across substances (alcohol, smoking, and other drugs), across
psychiatric diagnosis (bipolar disorder, schizoaffective disorder, and schizophrenia), across
race and ethnicity (African American, Hispanic, Asian, and European American), across
genders, and across age groups. This is the first large-scale study to robustly demonstrate
these associations across subgroups. Although substance use among individuals with
psychotic disorders has been documented 12,13,20,31, this study shows that there is a
continuing pressing need to target smoking, alcohol, marijuana, and drug use among
individuals with severe mental illness.
The most striking finding of this study is the evidence that societal-level protective effects
do not extend to individuals with severe mental illness. Specifically, we found that among
groups with lower than average rates of substance use (Hispanics and Asians relative to
European Americans, and females relative to males), the protective effects of belonging to
these groups did not carry over to individuals with severe psychotic disorder: the odds of
substance use increased to mitigate the protective effects. For example, relative to non-
Hispanic whites, individuals of Hispanic ethnicity have lower rates of heavy alcohol use in
controls (5.7% of n=3,424 in Hispanics, 8.1% of n=3,748 in non-Hispanic European
Americans, p<0.0001). However, individuals of Hispanic descent with severe psychotic
illness have higher rates of heavy alcohol use than non-Hispanic European Americans
(28.8% of n=1,583 in Hispanics, 27.3% of n=4,343 in non-Hispanic whites, p=0.001). This
highlights the need for targeting substance use specifically among individuals with severe
psychotic illness, as protective influences may not carry over from the general population.
The strongest associations between severe psychotic illness and substance use were seen
with cigarette use. This is notable because most of the mortality seen in severe psychiatric
illness is due to smoking related disorders. Also, it appears that recent public health efforts
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that have successfully decreased smoking in the general population have not been effective
in individuals with severe psychotic disorder. Specifically, the decrease in smoking among
individuals under age 30 that has been seen among the general population 32 and is present
in the controls in this dataset does not extend to cases: the OR of smoking daily for a month
or more is 8.2 among individuals younger than 30, which is significantly higher than the OR
of 5.2 among individuals age 30-49, and the OR of 3.9 among individuals age 50 or older
(interaction p=4.5 × 10−5). Given that (1) early mortality in cases is largely due to
cardiovascular and pulmonary disease, and (2) many psychotropic medications used to treat
psychotic symptoms have severe metabolic side effects that increase the risk of diabetes and
cardiovascular disease, it is imperative that we specifically target smoking in these
individuals. This is consistent with relatively recent calls for the field of psychiatry to
specifically target smoking in severe mental illness15.
Although these data illuminate characteristics of substance use in psychotic disorders in a
large, multi-ethnic population, further study is required to better understand the nature of the
comorbidity between psychotic disorders and substance dependence. The first step is to
specifically evaluate comorbid substance dependence in individuals with severe psychotic
illness, rather than individual measures of use as assessed in this study. In addition, the
validity and reliability of this series of questions has not been established in any population.
However, this series of questions was extracted from the DIGS, a standardized instrument
with high test/retest validity and reliability. A further limitation of this study is that it is not a
population survey. Because the individuals were not randomly sampled, there may be biases
in the dataset that limit extrapolation of the rates of substance use to the general populations
of both cases with severe psychotic illness and controls without a personal or family history
of bipolar disorder or schizophrenia. However, the sample was not selected for substance
use, so therefore the odds ratios of substance use for cases versus controls should be
accurate.
Nicotine, alcohol and other drugs of abuse target dopaminergic, glutamatergic, and
GABAergic transmission, which are also involved in the pathophysiology of severe mental
illness. Specifically, nicotine can increase the metabolism of anti-psychotics by activation of
the cytochrome P450 enzymes 33, and is thus hypothesized to help reduce side effects of
individuals taking antipsychotics. Conversely, exposure to substances increases risk of
severe mental illness: marijuana use at age 16 is associated with psychosis at age 19 34, and
smoking precedes the onset of symptoms of mental illness 35,36. Additionally, substance use
leads to higher rates of psychiatric emergencies and hospitalizations 37. This highlights the
importance of understanding the biological connection between substance use and severe
mental illness.
In summary, the prevalence of substance use in severe psychosis has been underestimated,
and spans social and cultural strata. This is the largest study of substance use in individuals
with severe psychotic illness to date. The study not only highlights the comorbid pathology
of substance use among those with severe psychotic illness, it also suggests that public
health efforts to reduce substance use have not been successful in one of our most vulnerable
populations, individuals with severe psychotic illness. It is time to use our recent scientific
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and public health advancements to improve scientific understanding of the comorbidity
between substance use and psychotic disorders, and improved treatment of both.
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Frequency of alcohol (Figure 1A), smoking (Figure 1B), marijuana (Figure 1C) and other
drug (Figure 1D) use contrasted among subgroups. Odds ratios correspond to odds of the
prevalence of the symptom among cases with chronic psychotic illness versus controls. The
OR's are contrasted with one another. When an OR is statistically different from the
reference (European descent for ethnicity, male for gender, and 30-49 for age group), this is
indicated by * (p<0.05) or ** (p<0.001).
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Table 2
Prevalence of substance use measures across psychiatric diagnoses.
Bipolar w/Psychosis Schizophrenia Schizoaffective-Bipolar Schizoaffective-Depressed Controls NSDUH Population survey
N 1,501 5,582 1,482 555 10,194 18,290
Alcohol > 4/day 26% 28% 29% 30% 8% 9.5%
100 cigarettes 74% 74% 80% 75% 33% 34%
daily smoking
> 1 month
71% 72% 79% 73% 29% 29%
Marijuana >
21xs in a year
52% 43% 54% 49% 18°% 16%
Recreational
drugs > 10xs
53% 35% 54% 45% 12% 10%
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Table 3
Prevalence of substance use measures compared between cases with chronic psychotic illness and controls.
ORs are calculated from logistic regression modeling probability of symptom as a function of diagnosis,
adjusted for gender, race, age, and data collection site.
OR
N estimate 95% CI lower 95% CI upper P
Alcohol > 4 /day 19,878 3.96 3.61 4.35 1.2 ×10−188
100 cigarettes 19,931 4.61 4.31 4.94 < 1.0 × 10−325
daily smoking > 1 month 19,882 5.11 4.78 5.46 < 1.0 × 10−325
Marijuana > 21xs in a year 19,859 3.47 3.23 3.72 2.6 ×10−254
Recreational drugs > 10xs 19,864 4.62 4.27 4.99 < 1.0 × 10−325
JAMA Psychiatry. Author manuscript; available in PMC 2015 March 01.
